Issue date: 20-October-2014 Revision date: 20-October-2014

Version number: 17



# SAFETY DATA SHEET

## 1. Identification

**Product identifier PURINETHOL TABLETS** 

Other means of identification

**Synonyms** PURI-NETHOL TABLETS \* PURINETHOL TABLETS 25 MG \* PURI-NETHOL TABLETS 50 MG \*

MERCAPTOPURINA WELLCOME COMPRIMIDOS \* MERCAPTOPURINE MONOHYDRATE.

FORMULATED PRODUCT

Recommended use of the chemical and restrictions on use

Medicinal Product Recommended use

> This safety data sheet is written to provide health, safety and environmental information for people handling this formulated product in the workplace. It is not intended to provide information relevant

to medicinal use of the product. In this instance patients should consult prescribing

information/package insert/product label or consult their pharmacist or physician. For health and safety information for individual ingredients used during manufacturing, refer to the appropriate

safety data sheet for each ingredient.

Restrictions on use No other uses are advised.

**Details of manufacturer or importer** 

Manufacturer

GlaxoSmithKline Australia 1061 Mountain Highway Melbourne, Victoria 3155

Australia General Information (Normal Business Hours): (03) 9721 6000

TRANSPORTATION EMERGENCY NUMBERS (available 24hrs/7days: multi-language response)

Australia Toll Free +(61) 2 9037 2994 International Toll Call +(1) 703 527 3887

# 2. Hazard(s) identification

## Classification of the hazardous chemical

Exempt from requirements - product regulated as a medicinal product, cosmetic product or medical device.

## Label elements, including precautionary statements

Exempt from requirements - product regulated as a medicinal product, cosmetic product or medical device.

### Other hazards which do not result in classification

Exempt from requirements - product regulated as a medicinal product, cosmetic product or medical device.

## 3. Composition/information on ingredients

#### **Mixture**

CAS number and other Concentration of Identity of chemical ingredients unique identifiers ingredients MERCAPTOPURINE MONOHYDRATE 16 - < 40.3 6112-76-1 CCI 3734 6-MERCAPTOPURINE

6-MERCAPTOPURINE MONOHYDRATE 1,7-DIHYDRO-6H-PURINE-6-THIONE MONOHYDRATE **THIOHYPOXANTHINE** 6-MERCAPTO-9H-PURINE MONOHYDRATE 1673 (GW ACN)

Material name: PURINETHOL TABLETS

SDS AUSTRALIA 110573

Starch 9005-25-8 10 - < 20
ARROWROOT STARCH
CORN STARCH
POTATO STARCH
RICE STARCH

MAGNESIUM STEARATE 557-04-0 < 1
STEARIC ACID, MAGNESIUM SALT
MAGNESIUM DISTEARATE
DIBASIC MAGNESIUM STEARATE
MAGNESIUM DISTEARATE
MAGNESIUM DISTEARATE
MAGNESIUM DISTEARATE, PURE

Other components below reportable levels

50 - < 60

## 4. First-aid measures

## Description of necessary first aid measures

**Inhalation** In case of accident by inhalation: remove casualty to fresh air and keep at rest. If breathing is

difficult, trained personnel should give oxygen. If not breathing, give artificial respiration. Get

medical attention immediately.

Skin contact Immediately flush with plenty of water for at least 15 minutes while removing contaminated clothing

and shoes. Remove and isolate contaminated clothing and shoes. Get medical attention

immediately.

**Eye contact** Rinse thoroughly with plenty of water for at least 15 minutes and consult a physician.

**Ingestion** If swallowed, rinse mouth with water (only if the person is conscious). Call a physician or poison

control centre immediately. Only induce vomiting at the instruction of medical personnel. Never

give anything by mouth to an unconsious person.

Personal protection for first-aid

responders

In the case of accident or if you feel unwell, seek medical advice immediately (show the label where possible). Ensure that medical personnel are aware of the material(s) involved, and take

precautions to protect themselves.

The need for pre-placement and periodic health surveillance must be determined by risk assessment. Following assessment, if the risk of exposure is considered significant then exposed individuals should undergo appropriate health surveillance that may include symptom enquiry.

clinical examination and monitoring of lead organ effects (e.g. full blood counts).

In the event of overexposure, individuals should receive post exposure health surveillance

focused on the most likely health effects (e.g. full blood counts).

**Symptoms caused by exposure** Prolonged exposure may cause chronic effects.

The following adverse effects have been noted with therapeutic use of this material: bone marrow

toxicity; nausea; vomiting; diarrhoea; anorexia; rash; hair loss.

Medical attention and special

treatment

No specific antidotes are recommended. Treat according to locally accepted protocols. For additional guidance, refer to the current prescribing information or to the local poison control

information centre.

## 5. Fire-fighting measures

**Extinguishing media** 

Suitable extinguishing

media

Foam. Dry chemical powder. Carbon dioxide (CO2). Water.

Unsuitable extinguishing

media

None known.

Specific hazards arising from

the chemical

During fire, gases hazardous to health may be formed.

Special protective equipment and precautions for fire

fighters

110573

Self-contained breathing apparatus and full protective clothing must be worn in case of fire.

Fire fighting

equipment/instructions

Use water spray to cool unopened containers.

Hazchem Code Not available.

**General fire hazards** Assume that this product is capable of sustaining combustion.

**Specific methods**Use standard firefighting procedures and consider the hazards of other involved materials.

Material name: PURINETHOL TABLETS SDS AUSTRALIA

# 6. Accidental release measures

## Personal precautions, protective equipment and emergency procedures

For non-emergency personnel

Keep unnecessary personnel away. Keep people away from and upwind of spill/leak. Keep out of low areas. Wear appropriate personal protective equipment. Do not touch damaged containers or spilled material unless wearing appropriate protective clothing. Ensure adequate ventilation. Local authorities should be advised if significant spillages cannot be contained. For personal protection,

For emergency responders

Keep unnecessary personnel away. Use personal protection recommended in Section 8 of the SDS.

**Environmental precautions** 

Avoid release to the environment. Contact local authorities in case of spillage to drain/aquatic environment. Prevent further leakage or spillage if safe to do so. Do not contaminate water. Avoid discharge into drains, water courses or onto the ground.

Methods and materials for containment and cleaning up

Stop the flow of material, if this is without risk. Collect spillage. Prevent entry into waterways, sewer, basements or confined areas. Following product recovery, flush area with water. For waste disposal, see section 13 of the SDS.

# 7. Handling and storage

Precautions for safe handling

Obtain special instructions before use. Do not handle until all safety precautions have been read and understood. Do not taste or swallow. Avoid contact during pregnancy/while nursing. Provide adequate ventilation. Wear appropriate personal protective equipment. Observe good industrial hygiene practices. When using, do not eat, drink or smoke. Wash hands thoroughly after handling. Avoid release to the environment. Do not empty into drains.

Conditions for safe storage, including any incompatibilities

Store locked up. Store in original tightly closed container. Store away from incompatible materials (see Section 10 of the SDS).

Value

Note

# 8. Exposure controls and personal protection

Control parameters

Components

Follow standard monitoring procedures.

Type

#### Occupational exposure limits

**GSK** 

Components	Турс	Value	11010
MAGNESIUM STEARATE (CAS 557-04-0)	OHC	1	
MERCAPTOPÚRINE MONOHYDRATE (CAS 6112-76-1)	8 HR TWA	10 mcg/m3	REPRODUCTIVE HAZARD, CARCINOGEN
	OHC	4	REPRODUCTIVE HAZARD, CARCINOGEN
Australia. National Workplace Ol	ELs (Workplace Exposure Standa	ards for Airborne Contamina	nts, Appendix A)

	OHC	4	REPRODUCTIVE HAZARD, CARCINOGEN
Australia. National Workplace OE Components	Ls (Workplace Exposure Star Type	ndards for Airborne Contamin Value	ants, Appendix A) Form
MAGNESIUM STEARATE (CAS 557-04-0)	TWA	10 mg/m3	Inhalable dust.
Starch (CAS 9005-25-8)	TWA	10 mg/m3	Inhalable dust.
Australia. OELs. (Adopted Nation Environment)	al Exposure Standards for At	mospheric Contaminants in tl	ne Occupational
Components	Туре	Value	Form
MAGNESIUM STEARATE (CAS 557-04-0)	TWA	10 mg/m3	Inspirable dust.
Starch (CAS 9005-25-8)	TWA	10 mg/m3	Inspirable dust.
US. ACGIH Threshold Limit Value	es		
Components	Туре	Value	
MAGNESIUM STEARATE (CAS 557-04-0)	TWA	10 mg/m3	
Starch (CAS 9005-25-8)	TWA	10 mg/m3	
UK. EH40 Workplace Exposure Li	mits (WELs)		
Components	Type	Value	Form
Starch (CAS 9005-25-8)	TWA	4 mg/m3	Respirable.
		10 mg/m3	Inhalable

No biological exposure limits noted for the ingredient(s).

Material name: PURINETHOL TABLETS

**Biological limit values** 

SDS AUSTRALIA

110573

## **Exposure guidelines**

## Appropriate engineering controls

No exposure standards allocated.

An Exposure Control Approach (ECA) is established for operations involving this material based upon the OEL/Occupational Hazard Category and the outcome of a site- or operation-specific risk assessment. Use process enclosures, local exhaust ventilation, or other engineering controls to control airborne levels below recommended exposure limits. Good general ventilation (typically 10 air changes per hour) should be used. Ventilation rates should be matched to conditions. If applicable, use process enclosures, local exhaust ventilation, or other engineering controls to maintain airborne levels below recommended exposure limits. If exposure limits have not been established, maintain airborne levels to an acceptable level. Ensure adequate ventilation, especially in confined areas.

## Individual protection measures, for example personal protective equipment (PPE)

Eye/face protection Eye wash fountain is recommended. Wear safety glasses with side shields (or goggles).

Skin protection

**Hand protection** The choice of an appropriate glove does not only depend on its material but also on other quality

features and is different from one producer to the other. Glove selection must take into account

any solvents and other hazards present.

Wear appropriate chemical resistant clothing. Other

Respiratory protection When workers are facing concentrations above the exposure limit they must use appropriate

certified respirators.

Thermal hazards Wear appropriate thermal protective clothing, when necessary.

An occupational/industrial hygiene monitoring method has been developed for this material. For Hygiene measures advice on suitable monitoring methods, seek guidance from a qualified environment, health and

safety professional.

Always observe good personal hygiene measures, such as washing after handling the material and before eating, drinking, and/or smoking. Routinely wash work clothing and protective equipment to remove contaminants. Do not get this material on clothing. Wash contaminated clothing before reuse. When using, do not eat, drink or smoke. New or expectant mothers might be at greater risk from overexposure. Risk assessments must take this into consideration. Female employees anticipating pregnancy or with a confirmed pregnancy must be encouraged to notify an occupational health professional or their line manager. This will act as the trigger for individual re-assessment of the employee's work practices.

## 9. Physical and chemical properties

**Appearance** 

Solid. **Physical state** Tablet. Form

Colour Not available. Odour Not available. **Odour threshold** Not available. Not available. Melting point/freezing point Not available. Initial boiling point and boiling Not available.

range

Not available. Flash point Not available. **Evaporation rate** Flammability (solid, gas) Not available. Upper/lower flammability or explosive limits

Flammability limit - lower

Not available.

(%)

Flammability limit - upper

Not available.

Not available. Explosive limit - lower (%) Not available. Explosive limit - upper

(%)

Not available.

Vapour pressure Not available. Vapour density

Relative density Not available.

Solubility(ies)

Solubility (water) Not available.

Partition coefficient Not available.

(n-octanol/water)

Auto-ignition temperatureNot available.Decomposition temperatureNot available.ViscosityNot available.

# 10. Stability and reactivity

**Reactivity**The product is stable and non-reactive under normal conditions of use, storage and transport.

Chemical stability Material is stable under normal conditions.

Possibility of hazardous

reactions

No dangerous reaction known under conditions of normal use.

Conditions to avoid Contact with incompatible materials.

Incompatible materials Alkali metals. Isocyanates

Hazardous decomposition

products

Irritating and/or toxic fumes and gases may be emitted upon the products decomposition.

## 11. Toxicological information

Information on possible routes of exposure

**Inhalation** Health injuries are not known or expected under normal use. Inhalation of dusts may cause

respiratory irritation.

**Skin contact** Health injuries are not known or expected under normal use. Dust or powder may irritate the skin.

Eye contact Health injuries are not known or expected under normal use. Direct contact with eyes may cause

temporary irritation. Dust or powder may irritate eye tissue.

**Ingestion** Health injuries are not known or expected under normal use. Harmful if swallowed.

Symptoms related to exposure 

Irritant effects. Prolonged exposure may cause chronic effects.

The following adverse effects have been noted with therapeutic use of this material: bone marrow

toxicity; nausea; vomiting; diarrhoea; anorexia; rash; hair loss;.

Adverse effects might occur in the following organ(s) following overexposure: bone marrow and

formation of blood cells; liver; immune system.

Acute toxicity Health injuries are not known or expected under normal use. Harmful if swallowed.

Components Species Test results

MAGNESIUM STEARATE (CAS 557-04-0)

Acute

Oral

LD50 Rat > 2000 mg/kg

MERCAPTOPURINE MONOHYDRATE (CAS 6112-76-1)

Acute

Oral

LD50 Mouse

1250 mg/kg

Chronic

Oral

 LD
 Rat
 20 mg/kg/day, 6 months

 NOAEL
 Rat
 < 5 mg/kg/day, 6 months</td>

Skin corrosion/irritation Health injuries are not known or expected under normal use. Prolonged skin contact may cause

temporary irritation.

**Irritation Corrosion - Skin** 

MERCAPTOPURINE MONOHYDRATE Acute dermal irritation; OECD 404, Primary Irritation Index: 0

Result: negative Species: Rabbit

Irritation Corrosion - Skin: P.I.I. value

MAGNESIUM STEARATE

Material name: PURINETHOL TABLETS

110573

5DS AUSTRALIA

5 / 9

0

Serious eye damage/irritation Health injuries are not known or expected under normal use. Direct contact with eyes may cause

temporary irritation.

Eye

MERCAPTOPURINE MONOHYDRATE Acute ocular irritation; OECD 405, Kay and Calandra score =

4; maximum group mean score = 9.3

Result: Mild irritant Species: Rabbit IRE Assay

Result: Negative; not likely to be a severe irritant

Eye / Kay and Calandra class - Intact

MAGNESIUM STEARATE

Recovery Period: 2 days

Respiratory or skin sensitisation

Respiratory sensitisation Not available.

**Skin sensitisation** Health injuries are not known or expected under normal use.

Germ cell mutagenicity Health injuries are not known or expected under normal use. Contains a component that produced

mutagenicity in laboratory tests.

Mutagenicity

MERCAPTOPURINE MONOHYDRATE Ames Assay, GLP assay

Result: positive

Chromosomal Aberration Assay In Vitro, human peripheral

lymphocytes Result: positive

Mammalian cell mutation assay (CHO/HGPRT forward

mutation assay) Result: positive

Mouse Lymphoma Cell (L5178Y) Mutation Assay, GLP assay

Result: positive

Unscheduled DNA Synthesis, in vivo - in vitro

Result: negative

Carcinogenicity Health injuries are not known or expected under normal use. Contains a component listed as a

carcinogen by: (GSK).

**ACGIH Carcinogens** 

MAGNESIUM STEARATE (CAS 557-04-0)

Starch (CAS 9005-25-8)

A4 Not classifiable as a human carcinogen.

A4 Not classifiable as a human carcinogen.

Reproductive toxicity

This material contains components which have been classified as: Possible reproductive hazard.

May damage fertility. Potential embryo-foetal toxicity and teratogenicity. May cause harm to

breastfed babies.

Specific target organ toxicity -

single exposure

None known.

Specific target organ toxicity -

repeated exposure

May cause damage to organs through prolonged or repeated exposure.

MERCAPTOPURINE MONOHYDRATE Repeat dose non-clinical studies; clinical observation

Organ: Bone marrow; liver; immune system

Aspiration hazard Not available.

Other information Symptoms may be delayed.

12. Ecological information

**Ecotoxicity** Contains a substance which causes risk of hazardous effects to the environment.

Components Species Test results

MAGNESIUM STEARATE (CAS 557-04-0)

Aquatic

Acute Fish

EC50 Orange-red killfish (Adult Oryzias 130 mg/l, 96 hours

latipes)

MERCAPTOPURINE MONOHYDRATE (CAS 6112-76-1)

Acute

IC50 Activated sludge > 1000 mg/l, 3 hours

Material name: PURINETHOL TABLETS SDS AUSTRALIA

Components **Species Test results** Aquatic Acute Algae EC50 Green algae (Scenedesmus > 100 mg/l, 72 hours Static test subspicatus) Green algae (Scenedesmus **NOEC** 100 mg/l, 72 hours Static test subspicatus) Crustacea EC50 Water flea (Daphnia magna) 72 mg/l, 48 hours Static test NOEC Water flea (Daphnia magna) 32 mg/l, 48 hours Static test

# Persistence and degradability

**Photolysis** 

Half-life (Photolysis-atmospheric)

MAGNESIUM STEARATE 17 Hours Estimated

UV/visible spectrum wavelength

MAGNESIUM STEARATE 210 nm

**Hydrolysis** 

Half-life (Hydrolysis-neutral)

MERCAPTOPURINE MONOHYDRATE 34 - 88 Days Measured, pH 7 Buffer Solution

Biodegradability

Percent degradation (Aerobic biodegradation-inherent)

MAGNESIUM STEARATE 77 %, 28 days BOD

MERCAPTOPURINE MONOHYDRATE < 1 %, 28 days Modified Zahn-Wellens, Activated sludge

Percent degradation (Aerobic biodegradation-ready)

MAGNESIUM STEARATE 95 %, 22 days Sturm test

MERCAPTOPURINE MONOHYDRATE 11 %, 28 days Modified Sturm test.

Percent degradation (Aerobic biodegradation-soil)

MAGNESIUM STEARATE 50 %, 13 days

Bioaccumulative potential

Partition coefficient n-octanol / water (log Kow)

MERCAPTOPURINE MONOHYDRATE < -2.03

**Bioconcentration factor** 

(BCF)

MAGNESIUM STEARATE > 9999 Estimated

Mobility in soil

Adsorption

Soil/sediment sorption - log Koc

MAGNESIUM STEARATE 5.86 Estimated

Mobility in generalNot available.Other adverse effectsNot available.

## 13. Disposal considerations

Disposal methods Collect and reclaim or dispose in sealed containers at licensed waste disposal site. Do not allow

this material to drain into sewers/water supplies. Do not contaminate ponds, waterways or ditches

with chemical or used container. Dispose of contents/container in accordance with

local/regional/national/international regulations.

**Residual waste** Dispose of in accordance with local regulations. Empty containers or liners may retain some

product residues. This material and its container must be disposed of in a safe manner (see:

Disposal instructions).

**Contaminated packaging** Empty containers should be taken to an approved waste handling site for recycling or disposal.

Since emptied containers may retain product residue, follow label warnings even after container is

emptied.

# 14. Transport information

**IATA** 

Not regulated as dangerous goods.

Material name: PURINETHOL TABLETS SDS AUSTRALIA

## **IMDG**

Not regulated as dangerous goods.

Transport in bulk according to Not applicable.

Annex II of MARPOL 73/78 and the IBC Code

# 15. Regulatory information

# Safety, health and environmental regulations

**National regulations** 

This Material Safety Data Sheet was prepared in accordance with the Australia National Code of Practice for the Preparation of Material Safety Data Sheets (NOHSC: 2011.)

## Australia Medicines & Poisons Appendix A

Poisons schedule number not allocated.

# Australia Medicines & Poisons Appendix B

Poisons schedule number not allocated.

# Australia Medicines & Poisons Appendix C

Poisons schedule number not allocated.

# Australia Medicines & Poisons Appendix D

Poisons schedule number not allocated.

## Australia Medicines & Poisons Appendix E

Poisons schedule number not allocated.

# Australia Medicines & Poisons Appendix F

Poisons schedule number not allocated.

# Australia Medicines & Poisons Appendix G

Poisons schedule number not allocated.

## Australia Medicines & Poisons Appendix H

Poisons schedule number not allocated.

## Australia Medicines & Poisons Appendix I

Poisons schedule number not allocated.

## Australia Medicines & Poisons Appendix J

Poisons schedule number not allocated.

#### Australia Medicines & Poisons Appendix K

Poisons schedule number not allocated.

## Australia Medicines & Poisons Schedule 2

Poisons schedule number not allocated.

#### **Australia Medicines & Poisons Schedule 3**

Poisons schedule number not allocated.

# Australia Medicines & Poisons Schedule 4

Poisons schedule number not allocated.

#### **Australia Medicines & Poisons Schedule 5**

Poisons schedule number not allocated.

# Australia Medicines & Poisons Schedule 6

Poisons schedule number not allocated.

## Australia Medicines & Poisons Schedule 7

Poisons schedule number not allocated.

# Australia Medicines & Poisons Schedule 8

Poisons schedule number not allocated.

# Australia Medicines & Poisons Schedule 9

Poisons schedule number not allocated.

# **High Volume Industrial Chemicals (HVIC)**

Not listed.

# Importation of Ozone Deleting Substances (Customs(Prohibited imports) Regulations 1956, Schedule 10)

Not listed.

## National Pollutant Inventory (NPI) substance reporting list

Not listed.

# **Prohibited Carcinogenic Substances**

Not regulated.

## Prohibited Substances (National Model Regulation for the control of Workplace Hazardous Substances, Schedule 2 NOHSC:1005 (1994) as amended)

## Resricted Importation of Organochlorine Chemicals (Customs(Prohibited Imports) Regulations 1956, Schedule 9)

## **Restricted Carcinogenic Substances**

Not regulated.

# International regulations

### **Stockholm Convention**

Not applicable.

## **Rotterdam Convention**

Not applicable.

#### **Kyoto protocol**

Not applicable.

## **Montreal Protocol**

Not applicable.

## **Basel Convention**

Not applicable.

Country(s) or region

## **International Inventories**

Australia

Canada	Domestic Substances List (DSL)	No
Canada	Non-Domestic Substances List (NDSL)	No
China	Inventory of Existing Chemical Substances in China (IECSC)	No
Europe	European Inventory of Existing Commercial Chemical Substances (EINECS)	No
Europe	European List of Notified Chemical Substances (ELINCS)	No
Japan	Inventory of Existing and New Chemical Substances (ENCS)	No
Korea	Existing Chemicals List (ECL)	No
New Zealand	New Zealand Inventory	No
Philippines	Philippine Inventory of Chemicals and Chemical Substances (PICCS)	No

Australian Inventory of Chemical Substances (AICS)

Toxic Substances Control Act (TSCA) Inventory

## 16. Other information

United States & Puerto Rico

Issue date 20-October-2014 **Revision date** 20-October-2014

**GSK Hazard Determination** References

The information and recommendations in this safety data sheet are, to the best of our knowledge, Disclaimer

accurate as of the date of issue. Nothing herein shall be deemed to create any warranty, express or implied. It is the responsibility of the user to determine the applicability of this information and

the suitability of the material or product for any particular purpose.

Product and Company Identification: Product and Company Identification **Revision Information** 

Composition / Information on Ingredients: Ingredients

Physical & Chemical Properties: Toxicological Information:

Inventory name

Ecological Information: Degradation

Regulatory Information: Risk Phrases - Class.

Material name: PURINETHOL TABLETS

SDS AUSTRALIA 110573

No

On inventory (yes/no)\*

<sup>\*</sup>A "Yes" indicates that all components of this product comply with the inventory requirements administered by the governing country(s) A "No" indicates that one or more components of the product are not listed or exempt from listing on the inventory administered by the governing country(s).